Top Story

Addition of chemotherapy to radiation failed to improve outcomes in esophageal cancer

September 18, 2014

The addition of chemotherapy to radiation therapy increased gastrointestinal toxicity but did not confer significant improvement in dysphagia or survival among patients with advanced esophageal cancer, according to results of a multinational, randomized phase 3 trial presented at the ASTRO Annual Meeting.

The findings suggest radiation therapy alone remains an effective strategy for palliation and should remain the standard of care for these patients, researchers wrote.

Patent filed for injectable HBV, liver cancer drug in China

September 18, 2014
Biostar Pharmaceuticals has filed an invention and creation patent application in China for oleanolic acid injection for the treatment of hepatitis B virus infection and…
figure

Ramucirumab plus FOLFIRI improved OS in metastatic colorectal cancer

September 15, 2014
Ramucirumab plus FOLFIRI in combination with chemotherapy improved overall survival in metastatic colorectal cancer patients after progression on a bevacizumab-based…
figure

VT-122, sorafenib improved OS in patients with HCC

September 12, 2014
Patients with advanced hepatocellular carcinoma had an increased overall survival rate after treatment with a novel combination of etodolac and propranolol plus…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

Meeting News Coverage

Addition of chemotherapy to radiation failed to improve outcomes in esophageal cancer

September 18, 2014
The addition of chemotherapy to radiation therapy increased gastrointestinal toxicity but did not confer significant improvement in dysphagia or…

Patent filed for injectable HBV, liver cancer drug in China

September 18, 2014
Biostar Pharmaceuticals has filed an invention and creation patent application in China for oleanolic acid injection for the treatment of hepatitis B…
figure

Ramucirumab plus FOLFIRI improved OS in metastatic colorectal cancer

September 15, 2014
Ramucirumab plus FOLFIRI in combination with chemotherapy improved overall survival in metastatic colorectal cancer patients after progression on a…
figure

VT-122, sorafenib improved OS in patients with HCC

September 12, 2014
Patients with advanced hepatocellular carcinoma had an increased overall survival rate after treatment with a novel combination of etodolac and…

Continuous imaging system tracked radiation delivery in liver cancer patient

September 11, 2014
A patient with liver cancer at the University of Wisconsin Carbone Cancer Center recently received novel MRI-guided radiation therapy, marking the…
figure Cover Story Publication Exclusive

Cancer treatment during pregnancy ‘a constant balancing act’

HemOnc Today, September 10, 2014
Cancer during pregnancy traditionally has been a rare phenomenon.Through the last third of the 20th century, about 1 in 1,000 pregnant women…
figure In the Journals

Prediabetes increases risks for cancers overall by up to 15%

September 8, 2014
Presence of prediabetes at baseline is associated with a 15% increased risk of cancer overall and when adjusting for BMI, 
Industry News

WHO recommends generic name for liver cancer drug candidate

September 5, 2014
WHO’s International Nonproprietary Name group has recommended the generic name mipsagargin for GenSpera’s G-202 in the treatment of…
figure In the Journals

Higher Medicaid reimbursement linked to increased cancer screening rates

September 4, 2014
State-specific increased Medicaid reimbursement for office visits was significantly associated with a greater likelihood for breast, cervical and…
FDA News

FDA grants fast track designation to PEGPH20 program for metastatic pancreatic cancer

September 3, 2014
The FDA granted fast track designation today to Halozyme Therapeutics for its PEGPH20 program in treating patients with pancreatic cancer, according…
More Headlines »